Mayzent (Siponimod) vs Ponvory (ponesimod)

Mayzent (Siponimod) and Ponvory (Ponesimod) are both oral medications approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Mayzent is a sphingosine 1-phosphate receptor modulator that works by trapping immune cells in lymph nodes, reducing their ability to reach the central nervous system and cause nerve damage. Ponvory, also a sphingosine 1-phosphate receptor modulator, has a similar mechanism of action but differs in its receptor binding profile and may have a more rapid onset of action; however, the choice between the two should be based on individual patient factors, potential side effects, and the advice of a healthcare professional.

Difference between Mayzent and Ponvory

Metric	Mayzent (Siponimod)	Ponvory (ponesimod)
Generic name	Siponimod	Ponesimod
Indications	Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults	Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults
Mechanism of action	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate receptor modulator
Brand names	Mayzent	Ponvory
Administrative route	Oral	Oral
Side effects	Headache, hypertension, liver function test increases, bradycardia	Upper respiratory infection, elevated liver enzymes, high blood pressure, and bronchitis
Contraindications	Patients with a CYP2C93/3 genotype, recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure	Patients with hypersensitivity to ponesimod or any of its excipients
Drug class	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate receptor modulator
Manufacturer	Novartis	Janssen Pharmaceuticals

Efficacy

Efficacy of Mayzent (Siponimod) in Multiple Sclerosis

Mayzent (Siponimod) is an oral medication approved by the FDA for the treatment of multiple sclerosis (MS), specifically for relapsing forms of the disease, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Siponimod is a sphingosine 1-phosphate receptor modulator that works by trapping immune cells in lymph nodes, preventing them from entering the central nervous system where they could potentially cause nerve damage. Clinical trials have shown that Mayzent can significantly reduce the annual relapse rate in patients with relapsing forms of MS. It has also been shown to slow the progression of disability associated with the disease.

In the pivotal Phase III trial known as EXPAND, which evaluated the efficacy of Siponimod in secondary progressive multiple sclerosis (SPMS), the medication was found to reduce the risk of three-month confirmed disability progression when compared to placebo. The trial also indicated a reduction in the rate of brain volume loss and the number of new or enlarging lesions on MRI, which are key measures of MS disease activity and progression.

Efficacy of Ponvory (Ponesimod) in Multiple Sclerosis

Ponvory (Ponesimod) is another oral sphingosine 1-phosphate receptor modulator approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponesimod functions similarly to Siponimod by sequestering lymphocytes in lymph nodes, thus reducing their impact on the central nervous system. The efficacy of Ponvory was demonstrated in a Phase III clinical trial known as OPTIMUM, which showed that Ponvory was more effective than teriflunomide, another MS drug, in reducing annual relapse rates in patients with relapsing MS.

The OPTIMUM study also reported that Ponvory led to a reduction in the number of new gadolinium-enhancing lesions and new or enlarging T2 lesions as seen on MRI scans, which are indicative of disease activity. Furthermore, the study highlighted improvements in fatigue-related symptoms, which is a common and often debilitating symptom in individuals with MS. Ponvory's ability to reduce relapses and MRI-detected disease activity, along with its impact on fatigue, underscores its efficacy in managing relapsing forms of MS.

Regulatory Agency Approvals

Mayzent

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Ponvory

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Mayzent or Ponvory today

If Mayzent or Ponvory are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Mayzent

Buy Ponvory

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: